patients (who have different genetics and dietary patterns than other populations) has not been previously described. Moreover, sparse data are available on strategies for optimal dose titration when transitioning from a calcium-based to a polymer-based phosphate binder. Methods. This randomized, double-blind, dose-titration study compared sevelamer carbonate (starting dose 800 mg three times daily) with placebo over 8 weeks' duration in Chinese CKD patients on haemodialysis. Patients were required to be using calcium-based binders prior to study start. Results. In all, 205 patients were randomized (sevelamer, n = 135; placebo, n = 70); mean age was 48.6 years, 61% were male and the mean time on dialysis was 4.4 years. The mean serum phosphorus decreased significantly in patients treated with sevelamer carbonate [change −0.69 ± 0.64 mmol/L (−2.14 ± 1.98 mg/dL)] but remained persistently elevated with placebo [change −0.06 ± 0.57 mmol/L (−0.19 ± 1.76 mg/dL)] (P < 0.0001). When compared with placebo, sevelamer carbonate treatment resulted in statistically significant greater mean reductions from baseline in serum total (−17.1 versus −3.3%) and low-density lipoprotein cholesterol (−33.5 versus −7.6%) (P < 0.0001 for both). Sevelamer carbonate was well tolerated with 96% adherence compared with 97% adherence in the placebo arm. Overall, adverse events experienced by patients in the sevelamer carbonate and placebo treatment groups were similar and consistent with their underlying renal disease.
Conclusions. This study demonstrated that hyperphosphataemia developed quickly following the cessation of phosphate binders and remained persistently elevated in end-stage CKD in the placebo-treated group. Gradually titrating up sevelamer carbonate from an initial dose of 2.4 g/day to an average daily dose of 7.1 ± 2.5 g/day was well tolerated, safe and efficacious in contemporary Chinese haemodialysis patients.
I N T RO D U C T I O N
Hyperphosphataemia is common in patients with chronic kidney disease (CKD), and failure to control this condition may be associated with debilitating sequelae and increased mortality and can lead to secondary hyperparathyroidism, which often results in renal osteodystrophy [1] . Hyperphosphataemia has also emerged as one of the more important risk factors for mortality in CKD patients on dialysis. The association between serum phosphorous and mortality is statistically significant, with an increasing risk of death as serum phosphorus levels increase [2] [3] [4] [5] [6] [7] [8] . Although there is no direct current evidence that lowering serum phosphorus improves mortality in haemodialysis patients, the results from the Accelerated Mortality in Renal Replacement study, a large, prospective, cohort trial, demonstrated that CKD patients not on dialysis had a lower mortality rate once dialysis was initiated if their pre-dialysis care included the use of phosphate binders [9] . Therefore, the current understanding in the clinical practice of nephrology, based on the literature, supports the position that hyperphosphatemic CKD patients should be treated with phosphate binders.
Despite conventional wisdom, there is very little clinical evidence on how hyperphosphatemic CKD patients respond in the absence of phosphate-binding treatment. Few placebocontrolled studies have been conducted in CKD patients on dialysis, and those that have been conducted used fixed doses of an active phosphate binder [10] [11] [12] .
Sevelamer hydrochloride is a non-absorbed, non-calcium-, non-metal-containing phosphate binder. A 2-week placebocontrolled trial was conducted in patients treated with sevelamer hydrochloride [10] . In this short study, the reduction in serum phosphorus levels was significantly greater in patients treated with sevelamer compared with placebo. Open-label, dose-titration studies have demonstrated sevelamer hydrochloride effectively controls hyperphosphataemia in patients with CKD [13] [14] [15] [16] , and active-controlled studies demonstrated sevelamer has similar efficacy as calcium-based phosphate binders [17] [18] [19] .
Sevelamer carbonate has been developed as an improved buffered form of sevelamer and has the same polymeric structure as sevelamer hydrochloride, except carbonate replaces chloride as the anion. The carbonate counterion in sevelamer carbonate provides alkali supplementation that may provide a benefit to CKD patients who typically develop metabolic acidosis as a result of underlying kidney insufficiency and impaired renal hydrogen ion excretion. Randomized, crossover studies have demonstrated sevelamer carbonate is therapeutically equivalent to sevelamer hydrochloride [20] [21] , but no placebo-controlled studies of sevelamer carbonate have been conducted.
The purpose of the current study was to (i) assess the efficacy and safety of sevelamer carbonate in a contemporary cohort of dialysis-dependent patients and (ii) to provide information about sevelamer dose titration, which leads to improved tolerability of a polymer-based phosphate binder.
M AT E R I A L S A N D M E T H O D S

Patient selection
Patients aged ≥18 years receiving maintenance haemodialysis for 30 days or longer at 18 nephrology centres in the People's Republic of China were enrolled into this study from March 2010 to September 2010. The laboratory criteria for inclusion included a serum phosphorus level >1.78 mmol/L (>5.51 mg/dL) after phosphate binder withdrawal and an intact parathyroid hormone (iPTH) measurement ≤1000 pg/mL at screening. Willingness to maintain pre-study doses of lipid and vitamin D medications for the duration of the study was also the inclusion criteria; no patients received cinacalcet before or during the trial as the drug is not approved for use in China. Patients were excluded from the study if they had a severe gastrointestinal motility disorder, poorly controlled diabetes mellitus, uncontrolled hypertension or any other clinically significant unstable medical condition.
The protocol and informed consent were reviewed and approved by an independent ethics committee. All patients provided written, informed consent prior to the initiation of any study-related activities. This research was carried out in accordance with the Good Clinical Practice guidelines and applicable regulations.
Study design
This was a randomized, double-blind, placebo-controlled, dose-titration study. Hyperphosphatemic [>1.78 mmol/L (>5.51 mg/dL)] patients following a 2-week phosphate binder washout period were randomized in a 2:1 (active:placebo) fashion, stratified by serum phosphorus [>1.78-2.10 mmol/L (>5.51-6.50 mg/dL) versus >2.10 mmol/L (>6.50 mg/dL)] and site to receive either sevelamer carbonate or placebo for the 8-week treatment period.
The starting dose of sevelamer carbonate was one 800-mg tablet three times daily with meals; placebo was also administered with meals. Samples for laboratory measurements were collected at bi-weekly visits. If the serum phosphorus level was >1.78 mmol/L (>5.51 mg/dL) at Weeks 2, 4 or 6, the patient was instructed at the next haemodialysis session to increase their study drug dose by one tablet per meal. At Week 8 or early termination (ET), study drug was stopped and patients returned to their usual phosphate binder(s).
Statistical analyses
The sample size was estimated assuming a 0.40-mmol/L (1.24-mg/dL) difference in change from baseline phosphorus levels between sevelamer carbonate and placebo; a standard deviation of 0.49 mmol/L (1.52 mg/dL) based on the data observed in the prior study [22] ; 90% power and a two-group Student's t-test with a two-sided 5% Type I error rate. Given these assumptions and using a 2:1 randomization, a total of 72 evaluable patients (48 active and 24 placebo) were required to demonstrate superiority over placebo. Approximately 180 patients (120 active and 60 placebo) were to be randomized to enrol 100 active patients, assuming a 17% withdrawal rate.
The safety set included all randomized patients who received at least one dose of study medication. The full analysis set (FAS) included the subset of the safety set evaluable patients with a baseline phosphorus measure and at least one post-Day 1 phosphorous measure ≤3 days after the date of the last study treatment. The FAS population represents the practically feasible intention-to-treat population, recognizing that the randomized subjects for whom no follow-up information exists cannot contribute meaningful information to the efficacy analysis. The per-protocol set (PPS) included all FAS evaluable patients with no significant protocol deviations. All safety assessments were performed on the safety set. All efficacy parameters were assessed for FAS. Confirmatory efficacy analyses were performed on the PPS.
The primary efficacy end point was the change from baseline to Day 57/ET (Week 8/ET) in serum phosphorus. The change from baseline to Day 57/ET in serum phosphorus was compared between the sevelamer carbonate treatment and placebo using Wilcoxon rank sum tests. The Type I error rate was contained at 5%. Subgroup analyses for the primary efficacy end point were also performed separately, recording change from baseline to Day 57/ET in serum phosphorus results by the baseline phosphorus level [≤2.10 mmol/L (≤6.50 mg/dL) versus >2.10 mmol/L (>6.50 mg/dL)], gender and age group (<65 versus ≥65 years). No formal hypothesis testing was performed to compare clinical differences at baseline between treatment groups.
The secondary efficacy end point was the change from baseline to Day 57/ET in serum lipids [total cholesterol and low-density lipoprotein (LDL) cholesterol]. The change from baseline to Day 57/ET in total cholesterol and LDL cholesterol was compared between the sevelamer carbonate treatment and placebo using Wilcoxon rank sum tests.
Serum phosphorus, total cholesterol and LDL cholesterol assessments measured at each study visit, as well as the change from baseline to each post-baseline time point, were summarized by treatment group. For total cholesterol and LDL cholesterol, the percent change from baseline to each post-baseline time point and to Day 57/ET was also summarized by treatment group. The Wilcoxon signed rank test was used to assess the significance of change from baseline to Day 57/ET within each treatment group.
Per cent adherence and the average maximum prescribed dose were summarized by treatment group. Adverse events (AEs) and changes in laboratory values were also summarized by treatment group.
R E S U LT S
Patients A total of 205 Chinese haemodialysis patients were randomized to sevelamer carbonate (n = 135) or placebo (n = 70). Due to concerns about a potentially high number of screen failures as well as high withdrawal rates in these haemodialysis study subjects, who have a disproportionate burden of morbidity and mortality, the study enrolled and randomized 205 patients. In all, 196 patients completed the study, 128 (94.8%) in the sevelamer carbonate group and 68 (97.1%) treated with placebo ( Figure 1) . Overall, the baseline characteristics of the patients were similar between treatment groups ( Table 1) . The most common prior phosphate binder treatments were calcium (in 57% of patients) and combination calcium plus vitamin D (in 42% of patients).
Medication adherence
The starting dose of sevelamer carbonate was 2.4 g/day, administered with meals; placebo was also administered with meals. The average maximum prescribed daily dose ± standard deviation (median, interquartile range [IQR]) was 8.8 ± 1.6 g/ day (median = 7.2, IQR 4.8, 9.6) placebo and 7.1 ± 2.5 g/day (median = 9.6, IQR = 7.2-9.6) sevelamer carbonate. The most frequent maximum prescribed daily dose was 9.6 g/day in both placebo and sevelamer carbonate treatment groups (74.3 and 40.0% of patients, respectively). The mean per cent adherence was similar between treatment groups (97% in the placebo and 96% in the sevelamer carbonate groups). A total of nine patients (two in placebo and seven in sevelamer carbonate) withdrew from the study after being treated. In the placebo withdrawals, one was for an AE and the other on the patient's wishes. In the sevelamer carbonate group, four patients withdrew for AEs and three for wish to withdraw and other reasons.
Efficacy
Serum phosphorus measured at each study visit is shown in Figure 2 . The mean phosphorus was similar between treatment groups at baseline, and the mean increases were similar in both treatment groups during the phosphate binder washout period. The mean serum phosphorus decreased over time from baseline in the sevelamer carbonate group, but not in the placebo group. The mean decrease in serum phosphorus was significantly greater in the sevelamer carbonate group compared with the placebo group ( Table 2) . The results in the PPS were similar to those of the FAS.
Subgroup analyses for the change in serum phosphorus were performed by baseline serum phosphorus [≤2.10 mmol/L (≤6.50 mg/dL) versus >2.10 mmol/L (>6.50 mg/dL)], gender (male versus female) and age (<65 years versus ≥65 years). In general, the results of the subgroup analyses were similar to those seen in the overall analyses.
Statistically significant decreases from baseline were observed in serum total cholesterol and LDL cholesterol in the sevelamer carbonate group ( Table 2 ). The mean decreases in total and LDL cholesterol from baseline to Day 57/ET were significantly greater in the sevelamer carbonate group compared with the placebo group (P values <0.0001). The results for PPS were similar to those of FAS.
Safety
Sevelamer carbonate was well tolerated. Overall, the treatment-emergent AEs experienced by the patients in the sevelamer carbonate and placebo treatment groups were similar. The most frequently reported treatment-related AE was gastrointestinal disorders. Overall, the nature, frequency and severity of gastrointestinal events were similar in both treatment groups, with the exception of constipation, which was more frequently reported in the sevelamer carbonate group (Table 3) .
A mean reduction from baseline to Day 57/ET in corrected calcium phosphorus product and non-high-density lipoprotein (HDL) cholesterol was noted in the sevelamer carbonate group (Table 4) . In addition, a mean increase from baseline to Day 57/ET in serum bicarbonate was noted in the sevelamer carbonate group (Table 4) . Minimal changes from baseline in these parameters were seen in the placebo group. There were no other clinically meaningful differences between treatment groups in the serum chemistry or haematology measures.
D I S C U S S I O N
Sevelamer carbonate is a non-absorbed, non-calcium-containing, non-metal polymeric phosphate binder, which has been found to effectively control serum phosphorus in randomized crossover studies [20, 21] . In this study, sevelamer carbonate significantly reduced serum phosphorus levels compared with placebo over 8 weeks. The initial increase in serum phosphorus during washout confirmed that patients were hyperphosphatemic. In the sevelamer carbonate group, there was a statistically significant and clinically meaningful reduction in serum phosphorus. The decline in serum phosphorus with sevelamer carbonate, but not placebo, confirmed that sevelamer carbonate was an effective phosphate binder.
The reductions seen with sevelamer carbonate treatment in the current study were similar to reductions that have been observed in previous sevelamer studies in dialysis patients [13] [14] [15] [16] [17] [18] [19] and CKD patients not on dialysis [23] . Thus, the results of this study confirmed that sevelamer carbonate is a safe and effective phosphate binder in a contemporary cohort of prevalent Chinese dialysis patients. The inclusion of the placebo group afforded the opportunity to examine the effect of sevelamer compared with no treatment. In addition to the effects on serum phosphorus level, sevelamer has been shown to bind bile acids [24] . Bile acid binding by ion exchange resins is a well-established method of lowering serum cholesterol. This study also compared the effects of sevelamer carbonate and placebo on serum lipid profiles. The results showed that sevelamer carbonate significantly reduced the total and LDL cholesterol levels compared with placebo. In the sevelamer carbonate group, there was a statistically significant and clinically meaningful reduction of 17 and 34% in total cholesterol and LDL cholesterol, respectively. The significantly greater declines in the total cholesterol and LDL cholesterol with sevelamer carbonate treatment demonstrated that sevelamer carbonate reduced serum lipids in CKD patients. The reductions seen with sevelamer carbonate in the current study were similar in magnitude to reductions that have been observed in previous sevelamer studies [13, 14, 16, 18, 23] .
Cardiovascular disease is the most common cause of death in dialysis patients [25] . Hyperphosphataemia is an important risk factor for cardiovascular morbidity and mortality in CKD patients on dialysis [2] [3] [4] [5] [6] [7] [8] . In addition to the risk hyperphosphataemia provides, the high incidence of abnormal lipid profiles in CKD patients may contribute to the excessive rate of cardiovascular events in these patients. In patients with normal renal function, cholesterol lowering is associated with reduction in myocardial infarction, stroke and death [26, 27] . While the AURORA [28] and 4D trials [29] did not result in a survival benefit in dialysis patients who received statin therapy, the results from the Study of Heart and Renal Protection (SHARP) demonstrated that cholesterol lowering also reduced the risk of major atherosclerotic events in CKD patients [30] . In this global study, which also included Chinese patients, CKD patients treated with ezetimibe plus simvastatin had one-sixth fewer heart attacks, strokes or operations to unblock arteries compared with CKD patients treated with placebo. The magnitude of LDL cholesterol reduction found in SHARP is similar to the reduction found in the current study.
Overall, the AEs experienced by patients in the sevelamer carbonate and placebo treatment groups in this study were similar and consistent with their underlying renal disease. The most frequently reported treatment-related events were gastrointestinal in nature and overall, the frequency and severity were similar in both treatment groups, with the exception of constipation, which was more frequent in the sevelamer carbonate group. The safety results found in this study were similar to those which have been observed in previous sevelamer studies in dialysis patients and CKD patients not on dialysis [10, [13] [14] [15] [16] [17] [18] [19] [20] [21] 23] . Acidosis is present in CKD patients in varying degrees as a consequence of reductions in glomerular filtration. Acidosis has been associated with adverse effects on bone metabolism [31] and increased malnutrition and inflammation [32] in haemodialysis patients. In addition, metabolic acidosis with a Table 3 . Treatment-related gastrointestinal AEs occurring in >4% of randomized patients in either treatment group: safety set Note: all P values were the same when the between-group comparisons were conducted using the Student's t-test. ET, end of treatment; LDL, low-density lipoprotein; SD, standard deviation. *P value is from the Wilcoxon rank sum test for between-group comparisons. **P value is from the Wilcoxon signed rank test for within-group comparisons.
serum bicarbonate level of <17.5 mmol/L (<17.5 mg/dL) has been independently associated with an increased risk of death in dialysis patients [6, 33] . Kidney Disease Outcomes Quality Initiative guidelines recommend that stabilized serum bicarbonate levels should be maintained at ≥22.0 mmol/L (≥22.0 mg/dL) in CKD patients on dialysis, regardless of arterial or venous blood source [1] . In this study, an expected increase in serum bicarbonate was noted in the sevelamer carbonate group. The carbonate counterion in sevelamer carbonate provides alkali supplementation that may provide a benefit to CKD patients who typically develop metabolic acidosis as a result of underlying kidney insufficiency and impaired renal hydrogen ion excretion. Of note, this study was conducted entirely in the People's Republic of China. Concerns may be raised regarding the generalizability and quality of these results considering it was solely conducted in one country. However, the reductions in serum phosphorus and LDL cholesterol observed in this study were similar in magnitude to reductions that have been observed in previous sevelamer studies in other regions [10, [13] [14] [15] [16] [17] [18] [19] [20] [21] 23] , which provide support for the validity of the current study results. While phosphate lowering is of central importance in the management of patients with CKD, data have not been described previously on the efficacy and safety of phosphate binders in haemodialysis patients who are Chinese (and therefore have distinct genetics and different dietary patterns from other populations).
In conclusion, sevelamer carbonate was a well-tolerated and effective treatment in CKD patients on dialysis. This study demonstrated that hyperphosphataemia develops quickly following the cessation of phosphate binders and remains persistently elevated when not treated. This study also demonstrated that sevelamer carbonate is an effective phosphate binder that also decreases LDL and total cholesterol, which is important given the increased cardiovascular risk profile in many dialysis patients.
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